BB-HB-331

March 15, 2016March 15, 2016

Benitec’s Investigational Drug for Hepatitis B Shows Promise in Mouse Model

News

Benitec Biopharma recently announced that a single injection of its investigational drug BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), displays a robust and durable ... Read more

December 17, 2015December 17, 2015

Benitec’s Hepatitis B Therapy Shows Efficacy in Early Preclinical Study

News

Benitec Biopharma, Ltd., announced that initial in vitro results demonstrated the efficacy of BB-HB-331, a ddRNAi-based therapeutic developed to treat and potentially cure hepatitis B with a single injection. These results were ... Read more